These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 18349390)

  • 1. Are vaccines making a comeback in non-small-cell lung cancer?
    Nemunaitis JJ
    J Clin Oncol; 2008 Mar; 26(9):1402-3. PubMed ID: 18349390
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical trials targeting lung cancer with active immunotherapy: the scope of vaccines.
    Raez LE; Santos ES; Mudad R; Podack ER
    Expert Rev Anticancer Ther; 2005 Aug; 5(4):635-44. PubMed ID: 16111464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic cancer vaccines in the treatment of non-small-cell lung cancer.
    Limacher JM; Spring-Giusti C; Bellon N; Ancian P; Rooke R; Bonnefoy JY
    Expert Rev Vaccines; 2013 Mar; 12(3):263-70. PubMed ID: 23496666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is vaccine therapy a renewed strategic approach for non-small-cell lung cancer therapy?
    Rossi A
    Expert Rev Vaccines; 2013 Jan; 12(1):5-7. PubMed ID: 23256734
    [No Abstract]   [Full Text] [Related]  

  • 5. Vaccines for the treatment of non-small cell lung cancer: a renewed anticancer strategy.
    Gridelli C; Rossi A; Maione P; Ferrara ML; Castaldo V; Sacco PC
    Oncologist; 2009 Sep; 14(9):909-20. PubMed ID: 19726457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.
    Ulloa-Montoya F; Louahed J; Dizier B; Gruselle O; Spiessens B; Lehmann FF; Suciu S; Kruit WH; Eggermont AM; Vansteenkiste J; Brichard VG
    J Clin Oncol; 2013 Jul; 31(19):2388-95. PubMed ID: 23715562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current immunotherapeutic strategies in lung cancer.
    Rüttinger D; Hatz RA; Jauch KW; Fox BA
    Surg Oncol Clin N Am; 2007 Oct; 16(4):901-18, x. PubMed ID: 18022551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer immunotherapy: phase II clinical studies with TG4010 (MVA-MUC1-IL2).
    Acres B
    J BUON; 2007 Sep; 12 Suppl 1():S71-5. PubMed ID: 17935281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Molecular biology of lung cancer series].
    Hiret S; Senellart H; Bennouna J
    Rev Mal Respir; 2010 Oct; 27(8):954-8. PubMed ID: 20965409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer.
    Neninger Vinageras E; de la Torre A; Osorio Rodríguez M; Catalá Ferrer M; Bravo I; Mendoza del Pino M; Abreu Abreu D; Acosta Brooks S; Rives R; del Castillo Carrillo C; González Dueñas M; Viada C; García Verdecia B; Crombet Ramos T; González Marinello G; Lage Dávila A
    J Clin Oncol; 2008 Mar; 26(9):1452-8. PubMed ID: 18349395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel targeted agents for lung cancer.
    West HJ
    Clin Lung Cancer; 2009 Mar; 10 Suppl 1():S41-6. PubMed ID: 19362946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of response to anticancer immunotherapy using gene signatures.
    Wang E; Bedognetti D; Marincola FM
    J Clin Oncol; 2013 Jul; 31(19):2369-71. PubMed ID: 23715576
    [No Abstract]   [Full Text] [Related]  

  • 13. Development of autoantibody signatures as novel diagnostic biomarkers of non-small cell lung cancer.
    Wu L; Chang W; Zhao J; Yu Y; Tan X; Su T; Zhao L; Huang S; Liu S; Cao G
    Clin Cancer Res; 2010 Jul; 16(14):3760-8. PubMed ID: 20501620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccines in non-small cell lung cancer: rationale, combination strategies and update on clinical trials.
    De Pas T; Giovannini M; Rescigno M; Catania C; Toffalorio F; Spitaleri G; Delmonte A; Barberis M; Spaggiari L; Solli P; Veronesi G; De Braud F
    Crit Rev Oncol Hematol; 2012 Sep; 83(3):432-43. PubMed ID: 22366114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Active immunotherapy for non-small-cell lung cancer: moving toward a reality.
    Perez CA; Santos ES; Raez LE
    Expert Rev Anticancer Ther; 2011 Oct; 11(10):1599-605. PubMed ID: 21999133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-small-cell lung cancer vaccine therapy: a concise review.
    O'Mahony D; Kummar S; Gutierrez ME
    J Clin Oncol; 2005 Dec; 23(35):9022-8. PubMed ID: 16219932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy.
    Tyagi P; Mirakhur B
    Clin Lung Cancer; 2009 Sep; 10(5):371-4. PubMed ID: 19808198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Monoclonal antibodies in the diagnosis and therapy of lung cancer].
    Campobasso N; Dammacco F
    Recenti Prog Med; 1991 Dec; 82(12):642-51. PubMed ID: 1667710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological markers of anti-tumor dendritic cells vaccine efficiency in patients with non-small cell lung cancer.
    Skachkova OV; Khranovska NM; Gorbach OI; Svergun NM; Sydor RI; Nikulina VV
    Exp Oncol; 2013 Jun; 35(2):109-13. PubMed ID: 23828386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination with BLP25 liposome vaccine to treat non-small cell lung and prostate cancers.
    North S; Butts C
    Expert Rev Vaccines; 2005 Jun; 4(3):249-57. PubMed ID: 16026241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.